Search

Your search keyword '"Schmidt, Albrecht G"' showing total 44 results

Search Constraints

Start Over You searched for: Author "Schmidt, Albrecht G" Remove constraint Author: "Schmidt, Albrecht G" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
44 results on '"Schmidt, Albrecht G"'

Search Results

1. Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction

2. Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19

3. Correction to: Informed consent and informed intervention: SARS‑CoV‑2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing

4. Informed consent and informed intervention: SARS-CoV-2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing

5. Allosteric targeting resolves limitations of earlier LFA-1 directed modalities

6. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction — Results of the Aldo-DHF trial

10. Association of HLA and Mutated CCR5 With the Clinical Course of the Disease in Subjects With mild / moderate disease following COVID-19 infection

12. Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction: The Aldo-DHF Randomized Controlled Trial

15. Rationale and design of the ‘aldosterone receptor blockade in diastolic heart failure’ trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF)

19. Galectin‐3 in patients with heart failure with preserved ejection fraction: results from the Aldo‐ DHF trial

21. High intracellular Na+preserves myocardial function at low heart rates in isolated myocardium from failing hearts

23. Type 1 Phosphatase, a Negative Regulator of Cardiac Function

26. Rescue of Contractile Parameters and Myocyte Hypertrophy in Calsequestrin Overexpressing Myocardium by Phospholamban Ablation

27. Interactions Between Phospholamban and β-Adrenergic Drive May Lead to Cardiomyopathy and Early Mortality

33. High intracellular Na+ preserves myocardial function at low heart rates in isolated myocardium from failing hearts

35. Differential regulation of p38 mitogen-activated protein kinase mediates gender-dependent catecholamine-induced hypertrophy

36. Combined phospholamban ablation and SERCA1a overexpression result in a new hyperdynamic cardiac state

37. Structural and functional implications of the phospholamban hinge domain: impaired SR Ca2+ uptake as a primary cause of heart failure

38. Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis

39. Maximal Inhibition of SERCA2 Ca2+Affinity by Phospholamban in Transgenic Hearts Overexpressing a Non-phosphorylatable Form of Phospholamban*

40. Relevance of stretch-induced phosphorylation of MAPK and p90rsk in human myocardium.

41. High intracellular Na+ preserves myocardial function at low heart rates in isolated myocardium from failing hearts.

42. Chronic SR Ca2+-ATPase inhibition causes adaptive changes in cellular Ca2+ transport.

43. Compensated hypertrophy of cardiac ventricles in aged transgenic FVB/N mice overexpressing calsequestrin.

44. Structural and functional implications of the phospholamban hinge domain: impaired SR Ca2+ uptake as a primary cause of heart failure.

Catalog

Books, media, physical & digital resources